EU must tackle clinical trials shortfalls as current lack of evidence is "appalling"
This article was originally published in SRA
Executive Summary
With devices becoming increasingly complex, competent authorities in the European Union must ensure there are sufficiently well-trained experts at notified body level, particularly for assessing innovative devices and for clinical trials. But authorities are facing difficult resource issues and finding experts is a real challenge. Dr Susanne Ludgate of the UK MHRA told Amanda Maxwell where the problems lie and what she believes to be the solutions.
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.